Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity-Reference-Cited by-同舟云学术

Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity

Published:2021-01-08 Issue: Volume: Page:
ISSN:0301-1623
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Krhut Jan^ORCID,Wohlfahrt Peter,Pudich Jiří,Kufová Eliška,Borovička Vladimír,Bílková Karolína,Sýkora Radek,Mokriš Jan,Cífková Renata,Zachoval Roman,Zvara Peter

Funder

Astellas Pharma Europe

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

http://link.springer.com/content/pdf/10.1007/s11255-020-02774-7.pdf

Reference26 articles.

1. Harris CJ, Lemack GE (2016) Neurourologic dysfunction: evaluation, surveillance and therapy. Curr Opin Urol 26(4):290–294

2. Kreydin E, Welk B, Chung D, Clemens Q, Yang C, Danforth T et al (2018) Surveillance and management of urologic complications after spinal cord injury. World J Urol 36(10):1545–1553

3. Watanabe M, Yamanishi T, Honda M, Sakakibara R, Uchiyama T, Yoshida K (2010) Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder. Int J Urol 17(11):931–936

4. Sugiyama H, Uemura O, Mori T, Okisio N, Unai K, Liu M (2017) Effect of imidafenacin on the urodynamic parameters of patients with indwelling bladder catheters due to spinal cord injury. Spinal Cord 55(2):187–191

5. Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC (2014) Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 33(1):17–30

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

2. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database;Frontiers in Pharmacology;2024-03-18

3. Examining the Safety of Mirabegron: An Analysis of Real-World Pharmacovigilance Data from the US FDA Adverse Event Reporting System (FAERS) Database;2024-01-03

4. Detrusor relaxing agents for neurogenic detrusor overactivity: a systematic review, meta‐analysis and network meta‐analysis;BJU International;2023-08-08

5. Efficacy and safety of mirabegron for treatment of neurogenic detrusor overactivity in adults with spinal cord injury or multiple sclerosis: a systematic review;Spinal Cord;2022-09-09